Gilead Attacks Post-Merger Claim to $50M Cancer Drug Bonus
Attorneys for Gilead Sciences Inc. pressed former Calistoga Pharmaceuticals Inc. officials Tuesday at trial in Delaware's Chancery Court to defend a $50 million post-merger bonus demand for Calistoga's stockholders filed after...To view the full article, register now.
Already a subscriber? Click here to view full article